Skip to content
ETEN
Findshops
Society

Finland Controls 53 New Psychoactive Substances and Tightens Synthetic Cannabinoid Rules

Illustrative photograph of Finnish government premises

On 5 November 2026, Finland’s government decided to bring 53 new psychoactive substances under control. At the same time, the synthetic cannabinoid MDMB-FUBINACA will be classified as a narcotic in Finland. The decree amendments take effect on 25 November 2026. They concern controls on new psychoactive substances, rather than any general legalisation of natural cannabis.

Why add 53 compounds at once?

According to Finland’s Ministry of Social Affairs and Health, all 53 substances fall within the category of designer drugs, or new psychoactive substances. Their molecular structures are often altered to create compounds that may not yet appear on existing lists. Finnish authorities have generally had to identify and classify such substances individually.

The new substances were identified by the Finnish Medicines Agency, Fimea, the police and customs. The agencies consider that they may cause harm to health. Bringing them under control aims to restrict marketing and distribution; it does not establish that all 53 have identical or fully researched risk profiles.

MDMB-FUBINACA receives a stricter classification

Helsinki street scene and cathedral
Helsinki, Finland. Illustrative photo: Eva Bronzini / Pexels.

In addition to the list of 53 substances, MDMB-FUBINACA’s legal status will change. Previously classified in Finland as a psychoactive substance prohibited on the consumer market, it will become a narcotic on 25 November. The United Nations Commission on Narcotic Drugs decided to place MDMB-FUBINACA under international control on 10 March 2026, following an assessment by the World Health Organization.

The name may suggest a connection to plant cannabinoids, but synthetic cannabinoids are not the same as natural cannabis or CBD. They are laboratory-made compounds that can act on cannabinoid receptors differently, and often much more strongly, than plant-derived THC. Their actual contents and dose may be difficult to judge, and severe poisoning can occur.

Is Finland also changing its broader system for designer drugs?

Yes. A separate bill aims to make future controls on new psychoactive substances faster. Under the proposal submitted on 22 October 2026, authorities could restrict entire groups of similar compounds rather than prohibiting each substance individually. This remains a proposal and should not be confused with the already approved November decree amendments.

Finland’s official rationale focuses particularly on preventing drug use and drug-related deaths among young people. Regulatory speed matters when manufacturers can make small structural changes and introduce new compounds faster than their risks can be fully assessed.

What does this mean for Estonia?

Changes in Finland do not automatically change Estonian law. The problem is nevertheless regional: synthetic substances cross national borders, and monitoring the European drug market requires cooperation between agencies. It is especially important to distinguish policy concerning plant cannabis from the acute health risks associated with synthetic cannabinoids.

Cannabis policy reform can be debated on the evidence while also recognising the need to control highly dangerous synthetic substances. Treating all these different substances as a single “cannabis problem” would make the discussion less precise.

Also read: CBD, CBG and CBN explained (in Estonian), and cannabis laws in Estonia in 2026.

Sources

Finnish government: 53 new psychoactive substances brought under control, 5 November 2026; Finnish government: proposal for faster regulation of designer drugs, 22 October 2026.

Featured image: Jyrki Kasvi / Wikimedia Commons, CC BY 2.5. The photograph is illustrative and does not depict the particular government meeting.

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *